Moser Sarah Sharman, Mazursky Orr Friedman, Shalev Hadas, Apter Lior, Chodick Gabriel, Siegelmann-Danieli Nava
Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Kaufman 4, Tel Aviv, 6801296, Israel.
Medical Affairs, Pfizer Pharmaceuticals Israel, Shenker 9, Herzlia, 4672509 Israel.
Future Oncol. 2023 Jul;19(21):1473-1483. doi: 10.2217/fon-2023-0176. Epub 2023 Aug 2.
To describe treatment journey and clinical outcomes after palbociclib initiation in HR+/HER2- breast cancer patients across multiple lines. Adult patients (n = 559) were identified in a population-based study between January 2018 and June 2020. Median follow-up time was 41.2 months. The starting dose was 125 mg for more than 85% of patients, and a third had dose reduction. Median time on treatment was 30.5 months for palbociclib + aromatase inhibitors for patients that received first-line treatment after metastatic diagnosis, and 12.6 months for palbociclib + fulvestrant across multiple lines, and longer for patients that had a dose reduction during treatment. At 48 months, 59.3 and 27.3% of patients were still alive, respectively. Subsequent lines resulted in median time on treatment of 4.4-7.7 months in both groups. Time on treatment for palbociclib was comparable to data from clinical trials, and follow-up allowed us to examine subsequent treatment after initial treatment failure. Dose reduction was common in the real-world setting and did not adversely affect efficacy.
描述多线治疗的HR+/HER2-乳腺癌患者开始使用哌柏西利后的治疗过程和临床结果。在一项基于人群的研究中，于2018年1月至2020年6月期间确定了成年患者（n = 559）。中位随访时间为41.2个月。超过85%的患者起始剂量为125mg，三分之一的患者进行了剂量降低。对于转移性诊断后接受一线治疗的患者，哌柏西利+芳香化酶抑制剂的中位治疗时间为30.5个月，多线使用哌柏西利+氟维司群的中位治疗时间为12.6个月，治疗期间进行剂量降低的患者治疗时间更长。在48个月时，患者的生存率分别为59.3%和27.3%。两组后续治疗的中位治疗时间均为4.4 - 7.7个月。哌柏西利的治疗时间与临床试验数据相当，随访使我们能够检查初始治疗失败后的后续治疗情况。在现实环境中，剂量降低很常见，且对疗效没有不利影响。
